Frank Eder, MD
Family Medicine · Binghamton, NYNPI 1528069077
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 61.0% of it on its own, with 53 other manufacturers making up the rest. Reporting peaked in 2019 at $18,405 and has fallen 88.8% since, to $2,064 in 2025. Among family medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,072 payments — averaging $66.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$43K
- Chiesi USA, Inc.$4K
- Pfizer$3K
- Janssen Research & Development, LLC$3K
- Novo Nordisk$2K
- Eli Lilly$2K
- plus $14K from 48 others
Across 5,861 payments — averaging $7886.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$34.4M
- Pfizer$4.6M
- Seqirus USA Inc$1.8M
- Sanofi Pasteur Inc.$900K
- Valneva Austria GmbH$833K
- Bavarian Nordic A/s$623K
- plus $3.1M from 20 others
What the payments were for
- Speaking & faculty fees$37,06552%
- Travel & lodging$13,02318%
- Food & beverage$20,80129%
- Education$1850%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$27,141
- UBRELVY$11,576
- PREVNAR - 13$2,101
- FARXIGA$346
- QULIPTA$243
- BREZTRI$241
- AIRSUPRA$238
- Repatha$149
- The Cologuard Plus Collection Kit$125
- Cologuard Collection Kit$124
- AIMOVIG$114
- INVOKANA$114
- BREZTRI AEROSPHERE$113
- SYMBICORT$113
- BEVESPI AEROSPHERE$113
- BYDUREON$113
- JARDIANCE$101
- Xhance$101
How this compares
$71,093 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 107 | $139,893 |
| OzempicSemaglutide | 95 | $132,226 |
| JardianceEmpagliflozin | 105 | $130,711 |
| MounjaroTirzepatide | 94 | $100,279 |
| FarxigaDapagliflozin Propanediol | 68 | $76,952 |
| Oxymorphone Hcl ErOxymorphone Hcl | 13 | $48,064 |
| XareltoRivaroxaban | 39 | $46,820 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $43,878 |
| JanuviaSitagliptin Phosphate | 29 | $37,334 |
| RybelsusSemaglutide | 17 | $21,216 |
| LinzessLinaclotide | 18 | $19,926 |
| MyrbetriqMirabegron | 28 | $19,578 |
| InvokanaCanagliflozin | 14 | $18,268 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $17,735 |
| CreonLipase/Protease/Amylase | 13 | $17,620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $781 | $157,554142 claims |
| Novo NordiskOzempic, Rybelsus | $2,119 | $153,442112 claims |
| PfizerEliquis | $2,781 | $139,893107 claims |
| Lilly USA, LLCMounjaro | $526 | $100,27994 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,735 | $97,257105 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy, Shingrix | $1,422 | $94,790152 claims |
| Johnson & JohnsonXarelto, Invokana | $356 | $65,08753 claims |
| AbbVieLinzess, Creon, Synthroid | $43,334 | $44,77497 claims |
| MerckJanuvia | $226 | $37,33429 claims |
| Astellas Pharma US IncMyrbetriq | $480 | $19,57828 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $84 | $4,10911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.
Other family medicine in Binghamton
- Sanjiv PatelBinghamton$41K
- Louis BonavitaEast Syracuse$674K
- Martin MahoneyBuffalo$520K
- Scott BrehautClinton$514K
- David St PeterSaratoga Springs$395K
- Matthew PabisNew York$222K
- Rajveer SachdevPomona$211K
- Eric SchnakenbergHalfmoon$190K
- James NorthGlens Falls$186K
- Eric BatesNew York$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.